Lung Cancer Clinical Trials

Showing 1441-1460 of 4,288 trials

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

NCT05500508

A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.

CancerSolid TumorSolid Carcinoma+17 more

Aminex Therapeutics, Inc.15 participantsStarted Nov 2022

Phoenix, Arizona, United States • Jacksonville, Florida, United States • Rochester, Minnesota, United States +4 more locations

COMPLETED

Real-World Immuno-Radiotherapy for Advanced NSCLC

NCT06747026

The optimal combination strategy for radiotherapy combined with immunotherapy (iRT) in advanced non-small-cell lung cancer (NSCLC) remains unclear, and there is a lack of real-world data to validate its efficacy. The objective of this study is to confirm the survival benefits of iRT in advanced NSCLC and to identify the optimal combination strategy for its use.

Lung Cancer Non-Small Cell Cancer (NSCLC)

Fengming Kong338 participantsStarted Jan 2015

Hong Kong, HongKong, Hong Kong

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Real-World Immuno-Radiotherapy for Advanced NSCLC

Related Searches

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Phase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer

FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC

Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study

Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer

A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil

A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

PRedictive Value of Multiparametric Dynamic WB 18F-FDG-PET Imaging on a LAFOV System for FIRST-line Chemo-immunotherapy Efficacy in Advanced Non-small-cell Lung Cancer: PROFIL-1

Clinical Trial to Evaluate the Efficacy and Safety of Pulsed Electric Field Ablation Devices in the Treatment of Lung Tumors

Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC

Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer

Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France

Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance

Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)